Literature DB >> 3884037

Assessment of immunological techniques in the diagnosis and prognosis of ocular malignant melanoma.

A J Cochran, W S Foulds, B E Damato, G E Trope, L Morrison, W R Lee.   

Abstract

Tests of cell mediated immunity (one and two stage leucocyte migration inhibition assays) and humoural immunity (membrane immunofluorescence and serum effects on leucocyte migration) were done with leucocytes and sera from 36 patients with uveal melanoma, five with conjunctival melanoma, 21 with non-malignant ocular disease, and 189 with cutaneous melanoma. Cell mediated reactivity with melanoma extracts and serum reactivity with cultured melanoma cells were significantly more frequent in the melanoma patients, but control donor reactivity was also relatively high. Maximum reactivity was found with cells or serum from those patients in whom, on pathological examination, the intraocular melanoma had penetrated the sclera and in patients with conjunctival melanoma. Maximum separation of melanoma patients from control donors was achieved by consideration of the results of several tests done simultaneously. These immunopathological studies were made during the period from 1972 to 1978. At follow-up in 1983 four of the five patients suffering from conjunctival melanoma had died from metastases, and 10 of the 36 with uveal melanoma had died from metastatic disease. The immunological reactions, while of some value in separating melanoma patients from those without melanoma, did not predict whether a particular patient with uveal melanoma would die of metastatic disease or would survive.

Entities:  

Mesh:

Year:  1985        PMID: 3884037      PMCID: PMC1040556          DOI: 10.1136/bjo.69.3.171

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  11 in total

1.  Cell-mediated immunity to melanoma-associated antigens in patients with ocular malignant melanoma.

Authors:  D H Char; L Jerome; J L McCoy; R B Herberman
Journal:  Am J Ophthalmol       Date:  1975-05       Impact factor: 5.258

2.  Tumor-associated antibodies in the serum of patients with ocular melanoma. III. Immunoperoxidase detection.

Authors:  N T Felberg; J M Pro-Landazuri; J A Shields; J L Federman
Journal:  Arch Ophthalmol       Date:  1979-02

Review 3.  A leucocyte migration technique for in vitro detection of cellular (delayed type) hypersensitivity in man.

Authors:  G Bendixen; M Soborg
Journal:  Dan Med Bull       Date:  1969-01

4.  Lymphoproliferative response as an index of cellular immunity in malignant melanoma of the uvea and its correlation with the histological features of the tumour.

Authors:  M S Sunba; A H Rahi; G Morgan; E J Holborow
Journal:  Br J Ophthalmol       Date:  1980-08       Impact factor: 4.638

5.  Autoimmune reactions in uveal melanoma.

Authors:  A H Rahi
Journal:  Br J Ophthalmol       Date:  1971-12       Impact factor: 4.638

6.  Formalinized tumour cells in the leucocyte migration inhibition test.

Authors:  C E Ross; A J Cochran; D E Hoyle; R M Grant; R M Mackie
Journal:  Clin Exp Immunol       Date:  1975-10       Impact factor: 4.330

7.  Inhibition of macrophage migration by choroidal malignant melanoma-associated antigens in patients with unveal melanoma.

Authors:  R S Manor; E Livni; H Joshua; I Ben-Sira
Journal:  Invest Ophthalmol Vis Sci       Date:  1978-07       Impact factor: 4.799

8.  Indirect leukocyte migration assay in patients with malignant melanoma.

Authors:  L J Morrison; A J Cochran; R M Mackie; C E Ross; G Todd; C Garland; G Garland
Journal:  Int J Cancer       Date:  1979-07-15       Impact factor: 7.396

9.  Leukocyte migration inhibition by cancer patients' sera.

Authors:  A J Cochran; R M Mackie; C E Ross; L J Ogg; A M Jackson
Journal:  Int J Cancer       Date:  1976-09-15       Impact factor: 7.396

10.  Tumor-associated antibodies in the serum of patients with ocular melanoma. IV. Correction for smooth muscle antibodies.

Authors:  N T Felberg; L A Donoso; J L Federman
Journal:  Ophthalmology       Date:  1980-06       Impact factor: 12.079

View more
  6 in total

1.  A caveat for T cell transfer studies: generation of cytotoxic anti-Thy1.2 antibodies in Thy1.1 congenic mice given Thy1.2+ tumors or T cells.

Authors:  Kyle C McKenna; Rodolfo D Vicetti Miguel; Kelly M Beatty; Richard A Bilonick
Journal:  J Leukoc Biol       Date:  2010-10-19       Impact factor: 4.962

2.  Monoclonal antibodies in detection of choroidal melanoma.

Authors:  P J Ringens; R van Haperen; C Vennegoor; P T de Jong; S G van Duinen; D J Ruiter; A W van der Kamp
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1989       Impact factor: 3.117

3.  Expression of HLA antigens in paraffin sections of uveal melanomas.

Authors:  M J Jager; D de Wolff-Rouendaal; A C Breebaart; D J Ruiter
Journal:  Doc Ophthalmol       Date:  1986-12-30       Impact factor: 2.379

4.  Expression of vascular endothelial growth factor-A, matrix metalloproteinase-9, and extravascular matrix patterns and their correlations with clinicopathologic parameters in posterior uveal melanomas.

Authors:  Afsun Sahin; Hayyam Kiratli; Figen Soylemezoglu; Gaye Guler Tezel; Sevgul Bilgic; Osman Saracbasi
Journal:  Jpn J Ophthalmol       Date:  2007-10-05       Impact factor: 2.447

5.  Detection and quantification of S-100 protein in ocular tissues and fluids from patients with intraocular melanoma.

Authors:  A J Cochran; G N Holland; R E Saxton; B E Damato; W R Foulds; H R Herschman; R Y Foos; B R Straatsma; W R Lee
Journal:  Br J Ophthalmol       Date:  1988-11       Impact factor: 4.638

6.  Lymphocytes cytotoxic to uveal and skin melanoma cells from peripheral blood of ocular melanoma patients.

Authors:  J Kan-Mitchell; P E Liggett; W Harel; L Steinman; T Nitta; J R Oksenberg; M R Posner; M S Mitchell
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.